Literature DB >> 27022132

Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma.

Peter J Cook1, Rozario Thomas1, Philip J Kingsley1, Fumiko Shimizu1, David C Montrose1, Lawrence J Marnett1, Viviane S Tabar1, Andrew J Dannenberg1, Robert Benezra2.   

Abstract

BACKGROUND: In glioblastoma (GBM), Id1 serves as a functional marker for self-renewing cancer stem-like cells. We investigated the mechanism by which cyclooxygenase-2 (Cox-2)-derived prostaglandin E2 (PGE2) induces Id1 and increases GBM self-renewal and radiation resistance.
METHODS: Mouse and human GBM cells were stimulated with dimethyl-PGE2 (dmPGE2), a stabilized form of PGE2, to test for Id1 induction. To elucidate the signal transduction pathway governing the increase in Id1, a combination of short interfering RNA knockdown and small molecule inhibitors and activators of PGE2 signaling were used. Western blotting, quantitative real-time (qRT)-PCR, and chromatin immunoprecipitation assays were employed. Sphere formation and radiation resistance were measured in cultured primary cells. Immunohistochemical analyses were carried out to evaluate the Cox-2-Id1 axis in experimental GBM.
RESULTS: In GBM cells, dmPGE2 stimulates the EP4 receptor leading to activation of ERK1/2 MAPK. This leads, in turn, to upregulation of the early growth response1 (Egr1) transcription factor and enhanced Id1 expression. Activation of this pathway increases self-renewal capacity and resistance to radiation-induced DNA damage, which are dependent on Id1.
CONCLUSIONS: In GBM, Cox-2-derived PGE2 induces Id1 via EP4-dependent activation of MAPK signaling and the Egr1 transcription factor. PGE2-mediated induction of Id1 is required for optimal tumor cell self-renewal and radiation resistance. Collectively, these findings identify Id1 as a key mediator of PGE2-dependent modulation of radiation response and lend insight into the mechanisms underlying radiation resistance in GBM patients.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cox-2; Id1; PGE2; glioblastoma; radioresistance

Mesh:

Substances:

Year:  2016        PMID: 27022132      PMCID: PMC5035519          DOI: 10.1093/neuonc/now049

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  47 in total

1.  Transcription of the dominant-negative helix-loop-helix protein Id1 is regulated by a protein complex containing the immediate-early response gene Egr-1.

Authors:  O Tournay; R Benezra
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

2.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.

Authors:  D Lyden; A Z Young; D Zagzag; W Yan; W Gerald; R O'Reilly; B L Bader; R O Hynes; Y Zhuang; K Manova; R Benezra
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

3.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

Review 4.  Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.

Authors:  Nikolaos A Dallas; Shaija Samuel; Ling Xia; Fan Fan; Michael J Gray; Sherry J Lim; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 5.  The role of COX-2 in intestinal inflammation and colorectal cancer.

Authors:  D Wang; R N Dubois
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

6.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

Authors:  D A Jones; D P Carlton; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.

Authors:  Barry R Davies; Armelle Logie; Jennifer S McKay; Paul Martin; Samantha Steele; Richard Jenkins; Mark Cockerill; Sue Cartlidge; Paul D Smith
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261

9.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

Review 10.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

View more
  29 in total

Review 1.  Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?

Authors:  Jianxiong Jiang; Jiange Qiu; Qianqian Li; Zhi Shi
Journal:  Trends Cancer       Date:  2017-01-11

2.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

Review 3.  Drugging cancer metabolism: Expectations vs. reality.

Authors:  David C Montrose; Lorenzo Galluzzi
Journal:  Int Rev Cell Mol Biol       Date:  2019-07-29       Impact factor: 6.813

4.  An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.

Authors:  Amit D Gujar; Son Le; Diane D Mao; David Y A Dadey; Alice Turski; Yo Sasaki; Diane Aum; Jingqin Luo; Sonika Dahiya; Liya Yuan; Keith M Rich; Jeffrey Milbrandt; Dennis E Hallahan; Hiroko Yano; David D Tran; Albert H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-07       Impact factor: 11.205

5.  Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.

Authors:  Mingyi Ju; Jingyi Fan; Yuanjiang Zou; Mingjie Yu; Longyang Jiang; Qian Wei; Jia Bi; Baohui Hu; Qiutong Guan; Xinyue Song; Mingyan Dong; Lin Wang; Lifeng Yu; Yan Wang; Hui Kang; Wei Xin; Lin Zhao
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 6.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

7.  Radiotherapy and Glioma Stem Cells: Searching for Chinks in Cellular Armor.

Authors:  Seamus P Caragher; Sean Sachdev; Atique Ahmed
Journal:  Curr Stem Cell Rep       Date:  2017-10-02

Review 8.  Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.

Authors:  Ezequiel Monferrer; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Sergio Abanades; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Metabolites       Date:  2021-04-23

9.  Anti-tumor effects of an ID antagonist with no observed acquired resistance.

Authors:  Paulina M Wojnarowicz; Marta Garcia Escolano; Yun-Han Huang; Bina Desai; Yvette Chin; Riddhi Shah; Sijia Xu; Saurabh Yadav; Sergey Yaklichkin; Ouathek Ouerfelli; Rajesh Kumar Soni; John Philip; David C Montrose; John H Healey; Vinagolu K Rajasekhar; William A Garland; Jeremy Ratiu; Yuan Zhuang; Larry Norton; Neal Rosen; Ronald C Hendrickson; Xi Kathy Zhou; Antonio Iavarone; Joan Massague; Andrew J Dannenberg; Anna Lasorella; Robert Benezra
Journal:  NPJ Breast Cancer       Date:  2021-05-24

Review 10.  Tumor microenvironment and radioresistance.

Authors:  Tatsuya Suwa; Minoru Kobayashi; Jin-Min Nam; Hiroshi Harada
Journal:  Exp Mol Med       Date:  2021-06-16       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.